In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Moderna (MRNA - Research Report), with a price target of $506.00. The company's shares opened today at $157.62.R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and CTI BioPharma. According to TipRanks, R. Cann has an average return of -3.2% and a 39.73% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $200.80 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $376.
https://www.tipranks.com/news/blurbs/moderna-mrna-gets-a-buy-from-brookline-capital-markets-3?utm_source=advfn.com&utm_medium=referral